A large-scale study of Ebola survivors found persistent health effects, including vision loss, hearing impairment, and cognitive decline. The study highlights the need for strategies to address the long-term health needs of survivors.
Researchers are investigating whether plasma from Ebola survivors can help treat patients with the disease. The study aims to determine if protective antibodies in the plasma can be used safely to reduce deaths in current and future outbreaks.
A newly formed high-level commission, in partnership with The Lancet, focuses on law's role in addressing pressing global health concerns. The Commission seeks to define the current landscape of law affecting global health and safety and highlight opportunities for improvement.
Researchers used TACC's Lonestar4 supercomputer to simulate and analyze data for various vaccine trial designs. They found that a phased-rollout randomized controlled trial would provide better information about the effectiveness of an Ebola vaccine.
In a deadly, rapidly spreading infectious disease like Ebola, traditional randomized clinical trials may be inadequate. Alternative trial designs can provide useful information and are morally justifiable, says a new article in the American Journal of Bioethics.
A study published in PLOS Medicine proposes a multi-stage approach to testing Ebola treatments, which may be quicker than traditional randomized trials while still providing robust results. This alternative design could potentially triage treatments faster and recommend them without further RCTs under certain circumstances.
Despite significant genetic mutations, Ebola's functional level has remained the same over the past four decades. This suggests that vaccines and treatments developed during current outbreaks may be effective against future outbreaks.
Researchers have found that the Ebola virus uses a protein called VP35 to remove its genetic material's protective coat, allowing it to replicate. Disrupting this process could potentially stop the spread of the disease.
Researchers at Texas Biomedical are exploring a novel mechanism for Filovirus detection using llama antibodies, which could lead to more sensitive diagnostic tools for Marburg and Ebola viruses. The goal is to develop streamlined tests that can detect all known and emerging strains of these viruses.
Researchers at UTMB have developed an Ebola vaccine that is both safe and effective with a single dose, providing protection against the deadly virus. The new vaccine employs a 'Trojan horse' approach, using a weakened form of the virus to trigger an immune response.
A new tool uncovers some surprises in diagnosing Ebola by identifying six key symptoms: contact with an infected person, diarrhea, loss of appetite, muscle pain, difficulty swallowing and absence of abdominal pain. This score can help clinicians risk-stratify patients during outbreaks.
A new diagnostic tool for Ebola virus disease was developed by Dr. Adam C. Levine at Rhode Island Hospital, which can help determine the likelihood of a patient having EVD based on six specific symptoms. The tool aims to facilitate timely and effective treatment for patients suspected to have the virus.
Low doses of Imatinib can stimulate the bone marrow to produce more innate immune cells, such as neutrophils and macrophages, to combat bacterial infections. This finding suggests that Imatinib or related drugs may be useful in treating a variety of infections in patients with weakened immune systems.
Two studies published in Infection Control & Hospital Epidemiology detail the challenges of caring for patients with suspected or confirmed Ebola Virus Disease (EVD) in hospitals. Key findings include staffing shortages, delays in patient care, and anxiety among staff and patients due to high-profile cases.
A phase 1 clinical trial found the VSV-EBOV Ebola vaccine to be safe and elicit a robust immune response, with 93% of volunteers developing anti-Ebola antibodies within two weeks. The vaccine's higher dose showed a stronger antibody response.
A Phase 1 trial of VSV-ZEBOV, an experimental Ebola vaccine, found it safe and elicited robust antibody responses in all 40 healthy adults who received it. The vaccine showed a favorable safety profile with mild or moderate fever experienced by 30% of participants.
Researchers found that camel antibodies protected uninfected mice from MERS and helped infected mice expunge the disease. The study suggests these antibodies might be therapeutic for MERS patients and protect uninfected household members and healthcare workers.
Two experimental Ebola vaccines have proven safe in a phase 2 clinical trial involving over 600 participants in Liberia. The trial may now advance to Phase 3 testing if the results are confirmed, with the ultimate goal of determining whether these vaccines can protect against Ebola virus disease.
A new Ebola vaccine has been shown to be highly effective and safe in monkeys, using an experimental platform that primes the immune system with the full complement of viral proteins. The vaccine was developed by researchers at the University of Wisconsin-Madison and may offer a promising alternative to existing vaccines.
New research reveals that Ebola progresses quickly and is fatal for young children, with a lower chance of survival compared to adults. The study found that nearly 90% of children under one year old and around 80% of children aged one to four years who are infected have died.
Researchers have developed a new Ebola vaccine based on the 2014 virus strain, showing it to be safe and provoking an immune response. In a phase 1 clinical trial, participants receiving high doses of the vaccine had a 100% positive immune response rate.
The Ebola epidemic has revealed critical weaknesses in the global public health system, including delayed responses and inadequate resources. Experts recommend adjusting WHO criteria for public health emergencies and increasing local authority involvement to develop culturally appropriate measures.
A new study reveals a cytomegalovirus-based vaccine provides protection against Ebola virus for over 14 months after a single dose, offering hope for preventing ebolavirus infection in African apes and reducing future human outbreaks. The innovative approach could help stabilize endangered ape populations and protect humans from the de...
A novel decision tree assesses quarantine's impact on disease spread and individual freedoms. The authors warn against premature quarantine measures without evidence-based data.
A study by University of Cambridge researchers found that closely-related fruit fly species show similar levels of virulence when infected with an RNA virus. The team's findings suggest a simple rule of thumb: if a pathogen causes high levels of mortality in one host, it may also be deadly in closely-related hosts.
The University of Illinois at Urbana-Champaign's SAWBO initiative uses animated educational videos to teach subsistence farmers how to construct raised planting beds and install drip irrigation systems. These techniques can increase agricultural productivity, conserve water, and even combat desertification.
Researchers found that severe disruptions to healthcare systems during the Ebola outbreak led to a significant reduction in measles vaccinations. This could result in an additional 2,000 to 16,000 deaths if a measles epidemic were to occur in affected countries.
A study predicts a rise in measles cases by 100,000 across West Africa due to Ebola-related health system disruptions, resulting in an additional 5,000 measles deaths. The research highlights the need for aggressive regional vaccination programs to counteract the steep downturn in immunization rates.
Researchers estimate that a large measles outbreak in West Africa could infect nearly twice as many people and kill thousands more due to significant decreases in vaccinations for childhood diseases. The Ebola crisis has led to a 45% increase in unvaccinated children, posing a substantial risk to public health.
A recent study by researchers at Georgia State University suggests that storing Ebola-infected sewage for a week or longer may not be sufficient to inactivate the virus, especially at lower ambient temperatures. The study used bacteriophage Φ6 as a stand-in for Ebola and found that holding times may need to be longer in such cases.
Researchers analyzed T and B cells from four Ebola survivors, finding surprisingly high levels of immune activation. The findings contradict previous research suggesting impaired immune responses and have implications for developing vaccines against Ebola.
A UCSB ecologist examines how human disturbance affects landscape and wildlife, revealing links between conservation and human health. She finds that land-use change increases plague transmission by moving rodents closer to human habitats, while environmental conditions affect flea infestations.
A physician who received an experimental Ebola vaccine after a needle stick injury developed mild symptoms but strong Ebola-specific immune responses. The study found the patient's clinical syndrome and laboratory evidence consistent with vaccination response, with no evidence of Ebola virus infection detected.
Researchers at the University of Washington have developed a new approach to diagnosing tuberculosis (TB) using oral swab samples, greatly improving on standard diagnostics. The method was tested in 20 healthy individuals and 20 TB patients, detecting TB in 18 out of 20 confirmed cases.
The Nebraska Biocontainment Unit implements a rigorous process to handle Ebola patients, including two blood samples confirmed undetectable for the virus before discharge. Environmental decontamination involves 48-hour isolation followed by manual disinfection, UVGI, and multiple air exchanges.
The NIH/National Institute of Allergy and Infectious Diseases has launched a clinical trial to test the safety and efficacy of ZMapp, an experimental Ebola treatment. The study will enroll adults and children with known Ebola infection and compare the treatment to standard care.
Human antibodies have been isolated and characterized that can neutralize the Marburg virus, a close cousin to Ebola. The discovery could lead to the development of an effective treatment and vaccine against these often lethal viruses. Researchers hope to complete clinical safety trials by the end of the year.
A Scripps Research Institute team has discovered an antibody that can target both Marburg and Ebola viruses, paving the way for new treatment options. The antibody works by binding to a vulnerable site on the virus's surface, preventing it from entering human cells.
A new method for producing immunoglobulin G (IgG) from human plasma has been developed, allowing for the treatment of patients with primary immune immunodeficiency and fighting various infectious diseases. The minipool technology is simple, efficient, and cost-effective, making it ideal for use in developing countries.
A collaborative team identified mechanisms involved in antibody response to the Marburg virus by studying a survivor's blood. The study reveals that the human immune system can effectively fight Marburg virus infections by producing antibodies.
Researchers discovered a new cellular factor critical to Ebola virus infection and identified Tetrandrine as a potent small molecule inhibiting the virus's entry into human white blood cells. The compound showed efficacy in preventing Ebola virus disease in mice without obvious side effects.
A new test from MIT researchers uses a simple paper strip to rapidly diagnose Ebola and other viral hemorrhagic fevers, such as yellow fever and dengue fever. The device takes about 10 minutes to produce results, allowing for quicker triage and isolation of patients.
Researchers found that maize production creates a perfect storm for plague transmission, with rodents and fleas increasing the risk of human infection. The study highlights the need for caution in expanding agriculture across Africa to prevent similar risks.
The JIKI clinical trial found encouraging signs of efficacy for favipiravir in individuals with high or moderate viral replication and less severe visceral lesions. In contrast, patients with very high viral loads and serious visceral involvement showed no efficacy from the treatment. These findings have implications for Ebola virus di...
Researchers found that airport screening often fails to detect half or more infected travelers, but can be improved by customizing to specific pathogens. Honest reporting by passengers is also crucial for effective detection and tracing.
The article highlights the weaknesses of the 2007 International Health Regulations (IHR) Treaty in responding to public health threats. Despite SARS strengthening the IHR, only 20% of countries met their obligations, leading to criticism of the treaty's effectiveness.
The Johns Hopkins Medicine has developed four web-based training modules on Ebola preparedness for emergency department personnel. These modules provide tools and resources to identify, triage, and manage patients at risk of Ebola, as well as planning processes and communication techniques.
A UNL researcher highlights the impact of climate change on the emergence of infectious diseases, citing examples of West Nile virus and Ebola as predictable outcomes. The expert calls for greater collaboration between public and veterinary health communities to address the growing threat.
A recent article highlights the importance of local health departments' roles in responding to global health security threats posed by infectious diseases. Key findings include the need for dedicated staff to interpret federal guidance, form partnerships with healthcare coalitions, and communicate accurate risk information. The Ebola e...
A recent NIH study found that Ebola virus can remain infectious in a body for at least seven days after death, with viral RNA detectable for up to 10 weeks. The research highlights the importance of safe handling practices and suggests oral swabbing as a reliable alternative for obtaining diagnostic samples.
Researchers found evidence of prior exposure to Ebola virus among patients with Lassa fever in Sierra Leone between 2011-2014. The discovery suggests that the deadly disease may have been circulating in the area for years before the 2014 outbreak, sparking hope for prevention and control strategies.
A University of Miami study found that short-form mindfulness meditation training reduces attentional lapses and mind wandering, enhancing cognitive resilience in military personnel. This technique can be beneficial for civilians in demanding professions as well.
Scientists developed an antiviral compound targeting VP24, a key protein in the Ebola virus, which protected 75% of infected monkeys. The compound, AVI-7537, was found to be safe and well-tolerated, offering hope for developing effective therapies against the deadly disease.
Researchers found that targeting a single protein, VP24, was sufficient to protect monkeys from Ebola virus infection. The medication, AVI-7537, also reduced viral load and liver/kidney damage in infected animals.
Researchers from Arizona State University and Georgia State University model the impact of timely diagnostic testing on Ebola's spread across populations. Early detection provides the opportunity to safely isolate and treat individuals before they become contagious, significantly reducing the number of infected individuals.
A team of researchers is exploring the blood of Ebola virus disease survivors to identify antibodies and immune cells that could help doctors fight future infections. The study aims to develop fully human antibodies targeting the Ebola viruses to guide the development of improved therapeutics and vaccines.
A report by The BMJ found that only around two-thirds of Ebola donations ($1.9 billion) reached affected countries, with delays in disbursements potentially contributing to the spread of the virus. Expert Karen Grépin argues that existing mechanisms need improvement to enable rapid deployment of funds for future public health threats.
A new study reveals that hepatitis C is more common than previously thought, with over 180 million people worldwide infected. The study also found that active infection rates are high in West Africa, where cultural and daily practices contribute to transmission.
The Liberia-NIH partnership is conducting a Phase 2/3 study to test the safety and efficacy of two experimental vaccines against Ebola virus infection. The trial will enroll approximately 27,000 healthy adults and those at high risk of infection, and will provide crucial information on potential countermeasures for future outbreaks.
Researchers at the University of Helsinki identified an alternative cell pathway promoting blood vessel growth that may explain why certain cancer therapies are failing to improve patient survival. This discovery could help clarify confusing trial results and potentially lead to new treatments for ovarian cancer and other cancers.